Try our Advanced Search for more refined results
November 24, 2020
Astellas Pharma Inc. et al v. Sandoz Inc. et al
Case Number:
1:20-cv-01589
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
- Abrams & Bayliss
- Heyman Enerio
- McCarter & English
- Morris James
- Phillips McLaughlin
- Shaw Keller
- Stamoulis & Weinblatt
- Young Conaway
Companies
- Alkem Laboratories Ltd.
- Allergan PLC
- Apotex Inc.
- Astellas Pharma Inc.
- Aurobindo Pharma Ltd.
- Lupin Ltd.
- Prinston Pharmaceutical Inc.
- Sandoz International GmbH
- Sawai Pharmaceutical Co. Ltd.
- Solco Healthcare US LLC
- Teva Pharmaceutical Industries Ltd.
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
June 28, 2023
Judge Says Pharma Industry Has 'Perverted' Hatch-Waxman
A Delaware federal judge has refused to further support his finding that a patent on bladder medication Myrbetriq is ineligible for patent protection as owner Astellas Pharma and various generic-drug makers fight over the invalidity finding at the Federal Circuit, but remarked that pharmaceutical companies have "perverted" the bounds of federal patent law.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login